These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38553507)

  • 1. No gender differences in the 24-month course of non-invasive liver fibrosis markers after DAA therapy in HCV-mono and HCV/HIV-coinfected patients.
    Collazos J; Pérez-Is L; de la Fuente B; Morano L; Rivas-Carmenado M; Rodriguez M; Romero-Favela A; de Jesús Fonseca-González G; Melón S; Diaz-Arias J; Valle-Garay E; Asensi V
    Sci Rep; 2024 Mar; 14(1):7534. PubMed ID: 38553507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 24-month decline of non-invasive liver fibrosis markers in HCV-mono and HCV/HIV coinfection after direct-acting antiviral therapy.
    Pérez-Is L; Collazos J; de la Fuente B; Morano L; Rivas-Carmenado M; Rodriguez M; Romero-Favela A; Fonseca-González GJ; Melón S; Valle-Garay E; Asensi V
    Sci Rep; 2022 Mar; 12(1):3828. PubMed ID: 35264591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term evolution in liver fibrosis and immune profile after direct-acting antivirals therapy in hepatitis C virus-human immunodeficiency virus co-infected patients.
    Laguno M; Martínez-Rebollar M; Casanova M; de Lazzari E; González-Cordón A; Torres B; Inciarte A; Mora L; Ugarte A; Ambrosioni J; Blanco JL; Martínez E; Mallolas J
    Clin Microbiol Infect; 2022 Apr; 28(4):610.e1-610.e7. PubMed ID: 34464735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.
    Quaranta MG; Ferrigno L; Tata X; D'Angelo F; Coppola C; Ciancio A; Bruno SR; Loi M; Giorgini A; Margotti M; Cossiga V; Brancaccio G; Dallio M; De Siena M; Cannizzaro M; Cavalletto L; Massari M; Mazzitelli M; De Leo P; Laccabue D; Baiocchi L; Kondili LA
    BMC Infect Dis; 2021 May; 21(1):413. PubMed ID: 33947337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients.
    Suárez-Zarracina T; Valle-Garay E; Collazos J; Montes AH; Cárcaba V; Carton JA; Asensi V
    J Viral Hepat; 2012 Oct; 19(10):685-93. PubMed ID: 22967099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?
    Kronfli N; Young J; Wang S; Cox J; Walmsley S; Hull M; Cooper C; Martel-Laferriere V; Wong A; Pick N; Klein MB;
    Clin Infect Dis; 2021 Aug; 73(3):468-477. PubMed ID: 32504083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection.
    Lledó GM; Carrasco I; Benítez-Gutiérrez LM; Arias A; Royuela A; Requena S; Cuervas-Mons V; de Mendoza C
    AIDS; 2018 Oct; 32(16):2347-2352. PubMed ID: 30096074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of chronic HCV genotype 1 coinfection.
    Boesecke C; Rockstroh JK
    Curr HIV/AIDS Rep; 2015 Sep; 12(3):326-35. PubMed ID: 26228050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain.
    Poveda E; Vispo E; Barreiro P; de Mendoza C; Labarga P; Fernández-Montero JV; Martin-Carbonero L; Soriano V
    Antivir Ther; 2012; 17(3):571-5. PubMed ID: 22293607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapies.
    Labarga P; Fernández-Montero JV; López M; Barreiro P; de Mendoza C; Sierra-Enguita R; Treviño A; Soriano V
    Antivir Ther; 2014; 19(8):799-803. PubMed ID: 24964405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender differences in liver fibrosis and hepatitis C virus-related parameters in patients coinfected with human immunodeficiency virus.
    Collazos J; Cartón JA; Asensi V
    Curr HIV Res; 2011 Jul; 9(5):339-45. PubMed ID: 21827383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients.
    Labarga P; Fernandez-Montero JV; de Mendoza C; Barreiro P; Pinilla J; Soriano V
    Antivir Ther; 2015; 20(3):329-34. PubMed ID: 25372299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals.
    Peters L; Laut K; Resnati C; Del Campo S; Leen C; Falconer K; Trofimova T; Paduta D; Gatell J; Rauch A; Lacombe K; Domingo P; Chkhartishvili N; Zangerle R; Matulionyte R; Mitsura V; Benfield T; Zilmer K; Khromova I; Lundgren J; Rockstroh J; Mocroft A;
    AIDS; 2018 Sep; 32(14):1995-2004. PubMed ID: 29912062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
    Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
    Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection.
    Malin JJ; Boesecke C; Schwarze-Zander C; Wasmuth JC; Schlabe S; Trebicka J; Spengler U; Llibre JM; Jou T; Vasylyev M; Clotet B; Rockstroh JK
    HIV Med; 2019 Mar; 20(3):230-236. PubMed ID: 30687989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
    Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
    J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similar recovery of liver function after response to all-oral HCV therapy in patients with cirrhosis with and without HIV coinfection.
    Macías J; Granados R; Téllez F; Merino D; Pérez M; Morano LE; Palacios R; Paniagua M; Frías M; Merchante N; Pineda JA;
    J Viral Hepat; 2019 Jan; 26(1):16-24. PubMed ID: 30141222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvements in liver transplant outcomes in patients with HCV/HIV coinfection after the introduction of direct-acting antiviral therapies.
    Shimada S; Ivanics T; Kitajima T; Shamaa T; Rizzari M; Collins K; Yoshida A; Abouljoud M; Moonka D; Zhang J; Lu M; Nagai S
    Transpl Infect Dis; 2022 Apr; 24(2):e13808. PubMed ID: 35157334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Characteristics and Treatment Outcomes of Patients with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection: Experience at a Single Center in Korea.
    Lim DH; Jeong JY; Nam S; Choi J; Kwon HC; Yoon YB; Kim Y; Chin B
    J Korean Med Sci; 2021 Nov; 36(46):e308. PubMed ID: 34845874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
    Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L;
    J Hepatol; 2021 Jan; 74(1):37-47. PubMed ID: 32798585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.